NITE - Sangamo 2018: Coming Up Short
Sangamo (SGMO) closed the book on 2018 last week when they hosted their 4Q18 earnings call. 2018 had started with tremendous promise following the October 2017 first-ever in vivo genome editing treatment and a second Pfizer (NYSE:PFE) gene regulation collaboration. The SB-525 hemophilia A gene therapy trial had moved into cohort 2 and new trial initiations were projected for beta-thalassemia, sickle cell disease, Fabry, MPS I and hemophilia B. Expectations for a catalyst-rich year created palpable excitement for both Sangamo and the genome medicine sector. Those